Section 69.50.208. Schedule III.

Unless specifically excepted by state or federal law or regulation or more specifically included in another schedule, the following controlled substances are listed in Schedule III:

(a) Stimulants. Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, whether optical, position, or geometric, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Any compound, mixture, or preparation in dosage unit form containing any stimulant substance included in Schedule II and which was listed as an excepted compound on August 25, 1971, pursuant to the federal Controlled Substances Act, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except for containing a lesser quantity of controlled substances;

(2) Benzphetamine;

(3) Chlorphentermine;

(4) Clortermine;

(5) Phendimetrazine.

(b) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

(1) Any compound, mixture, or preparation containing:

(i) Amobarbital;

(ii) Secobarbital;

(iii) Pentobarbital;

or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule;

(2) Any suppository dosage form containing:

(i) Amobarbital;

(ii) Secobarbital;

(iii) Pentobarbital;

or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;

(3) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid;

(4) Chlorhexadol;

(5) Embutramide;

(6) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal food, drug, and cosmetic act;

(7) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine: (<plus-minus˃)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;

(8) Lysergic acid;

(9) Lysergic acid amide;

(10) Methyprylon;

(11) Sulfondiethylmethane;

(12) Sulfonethylmethane;

(13) Sulfonmethane;

(14) Tiletamine and zolazepam or any of their salts—some trade or other names for a tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl) cyclohexanone, some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e][1,4]-diazepin-7(1H)-one flupyrazapon.

(c) Nalorphine.

(d) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof calculated as the free anhydrous base or alkaloid, in limited quantities as set forth in this subsection:

(1) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(2) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(3) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;

(4) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(5) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(6) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(7) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; and

(8) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(e) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts: Buprenorphine.

(f) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product. Some other names for dronabinol: [6a R-trans]-6a,7,8, 10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d] pyran-i-ol, or (-)-delta-9-(trans)-tetrahydrocannabinol.

(g) Anabolic steroids. The term "anabolic steroids" means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone, that promotes muscle growth and includes:

(1) 3β,17-dihydroxy-5a-androstane;

(2) 3α,17β-dihydroxy-5a-androstane;

(3) 5α-androstan-3,17-dione;

(4) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1-ene);

(5) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1-ene);

(6) 4-androstenediol (3β,17β-dihydroxy-androst-4-ene);

(7) 5-androstenediol (3β,17β-dihydroxy-androst-5-ene);

(8) 1-androstenedione ([5α]-androst-1-en-3,17-dione);

(9) 4-androstenedione (androst-4-en-3,17-dione);

(10) 5-androstenedione (androst-5-en-3,17-dione);

(11) Bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);

(12) Boldenone (17β-hydroxyandrost-1,4,-diene-3-one);

(13) Calusterone (7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);

(14) Clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one);

(15) Dehydrochloromethyltestosterone (4-chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3-one);

(16) Δ1-dihydrotestosterone (a.k.a. '1-testosterone') (17β-hydroxy-5α-androst-1-en-3-one);

(17) 4-dihydrotestosterone (17β-hydroxy-androstan-3-one);

(18) Drostanolone (17β-hydroxy-2α-methyl-5α-androstan-3-one);

(19) Ethylestrenol (17α-ethyl-17β-hydroxyestr-4-ene);

(20) Fluoxymesterone (9-fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one);

(21) Formebolone (2-formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one);

(22) Furazabol (17α-methyl-17β-hydroxyandrostano[2,3-c]-furazan);

(23) 13β-ethyl-17β-hydroxygon-4-en-3-one;

(24) 4-hydroxytestosterone (4,17β-dihydroxy-androst-4-en-3-one);

(25) 4-hydroxy-19-nortestosterone (4,17β-dihydroxy-estr-4-en-3-one);

(26) Mestanolone (17α-methyl-17β-hydroxy-5-androstan-3-one);

(27) Mesterolone (1α methyl-17β-hydroxy-[5α]-androstan-3-one);

(28) Methandienone (17α-methyl-17β-hydroxyandrost-1,4-dien-3-one);

(29) Methandriol (17α-methyl-3β,17β-dihydroxyandrost-5-ene);

(30) Methenolone (1-methyl-17β-hydroxy-5α-androst-1-en-3-one);

(31) 17α-methyl-3β,17β-dihydroxy-5a-androstane;

(32) 17α-methyl-3α,17β-dihydroxy-5a-androstane;

(33) 17α-methyl-3β,17β-dihydroxyandrost-4-ene;

(34) 17α-methyl-4-hydroxynandrolone (17α-methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one);

(35) Methyldienolone (17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one);

(36) Methyltrienolone (17α-methyl-17β-hydroxyestra-4,9-11-trien-3-one);

(37) Methyltestosterone (17α-methyl-17β-hydroxyandrost-4-en-3-one);

(38) Mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en-3-one);

(39) 17α-methyl-Δ1-dihydrotestosterone (17bβ-hydroxy-17α-methyl-5α-androst-1-en-3-one) (also known as '17-α-methyl-1-testosterone');

(40) Nandrolone (17β-hydroxyestr-4-en-3-one);

(41) 19-nor-4-androstenediol (3β, 17β-dihydroxyestr-4-ene);

(42) 19-nor-4-androstenediol (3α, 17β-dihydroxyestr-4-ene);

(43) 19-nor-5-androstenediol (3β, 17β-dihydroxyestr-5-ene);

(44) 19-nor-5-androstenediol (3α, 17β-dihydroxyestr-5-ene);

(45) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

(46) 19-nor-5-androstenedione (estr-5-en-3,17-dione);

(47) Norbolethone (13β, 17α-diethyl-17β-hydroxygon-4-en-3-one);

(48) Norclostebol (4-chloro-17β-hydroxyestr-4-en-3-one);

(49) Norethandrolone (17α-ethyl-17β-hydroxyestr-4-en-3-one);

(50) Normethandrolone (17α-methyl-17β-hydroxyestr-4-en-3-one);

(51) Oxandrolone (17α-methyl-17β-hydroxy-2-oxa-[5α]-androstan-3-one);

(52) Oxymesterone (17α-methyl-4,17β-dihydroxyandrost-4-en-3-one);

(53) Oxymetholone (17α-methyl-2-hydroxymethylene-17β-hydroxy-[5α]-androstan-3-one);

(54) Stanozolol (17α-methyl-17β-hydroxy-[5α]-androst-2-eno[3,2-c]-pyrazole);

(55) Stenbolone (17β-hydroxy-2-methyl-[5α]-androst-1-en-3-one);

(56) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);

(57) Testosterone (17β-hydroxyandrost-4-en-3-one);

(58) Tetrahydrogestrinone (13β, 17α-diethyl-17β-hydroxygon-4,9,11-trien-3-one);

(59) Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and

(60) Any salt, ester, or ether of a drug or substance described in this section. Such term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the secretary of the department of health and human services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this section.

The commission may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in subsection (a)(1) and (2) of this section from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances having a stimulant or depressant effect on the central nervous system.

The controlled substances listed in this section may be added, rescheduled, or deleted as provided for in RCW 69.50.201.

[ 2013 c 19 § 91; 2010 c 177 § 4; 1993 c 187 § 8; 1986 c 124 § 5; 1980 c 138 § 3; 1971 ex.s. c 308 § 69.50.208.]

NOTES:

Commission may change schedules of controlled substances: RCW 69.50.201.

2013 c 19 § 91; 2010 c 177 § 4; 1993 c 187 § 8; 1986 c 124 § 5; 1980 c 138 § 3; 1971 ex.s. c 308 § 69.50.208.